PIONEERING A NEW CLASS OF THERAPEUTIC ANTIBODIES
Our mission is to improve the treatment of cancer by creating and developing novel IgM and IgA antibodies.
IGM Biosciences Appoints M. Kathleen Behrens, Ph.D., to Board of Directors
January, 2019
Dr. Kathy Behrens brings 35 years of biotech and investment industry experience and leadership IGM...
IGM Biosciences Appoints Misbah Tahir as Chief Financial Officer
January, 2019
Mr. Tahir Brings More Than 20 Years of Financial and Strategic Planning Experience IGM Biosciences,...
IGM Biosciences Appoints Wayne Godfrey, M.D., as Vice President, Clinical Development
November, 2018
Pioneer in Cancer Immunotherapy Research and Clinical Lead for Kite/Gilead ZUMA-5 Program, Dr. Godfrey Joins...
IGM Biosciences Appoints Julie Hambleton, M.D., to Board of Directors
August, 2018
Dr. Hambleton Brings More Than 25 Years of Industry and Academic Experience MOUNTAIN VIEW, Calif.,...
IGM Biosciences Appoints Daniel S. Chen, M.D., Ph.D., as Chief Medical Officer; Names William Strohl, Ph.D., to Board of Directors
August, 2018
Dr. Daniel Chen, Former Global Head of Cancer Immunotherapy Development at Genentech/Roche and Noted Immuno-Oncology...